PubMed Health⌕ Search

PubMed · 3124606

Assessing changes in risk factor effect over multiple levels of severity.

Abstract

Use of the logistic function has become standard for regression of proportions onto risk factors, but where multiple levels of response are recorded, several different techniques are common. For most purposes, the "inclusive" method is most appropriate. However, if investigation is focused directly on the pattern of risk factor effects over levels of severity, the inclusive method is too conservative, because its overlapping categories tend to minimize any real differences among risk factor effects at separate levels. Several alternative techniques maximize these estimated differences, but interpretation of their results is much more sensitive to the assumed model than is estimation of category frequencies. In most cases, it is not possible to know precisely what model actually generated the data at hand. Therefore, a procedure is recommended which combines the safety of the inclusive method with an adjuvant technique called the "continuation ratio" method which has greater power to disclose differences between risk factor effects at different levels of response.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

C J MacLean. 1988. Assessing changes in risk factor effect over multiple levels of severity.. https://doi.org/10.1093/oxfordjournals.aje.a114841

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.

The peroxisome proliferator-activated receptor (PPAR) family of genes plays a major role in metabolic regulation. Unfortunately, the results of two recent, large event trials of PPAR agonists have been mixed. High rates of crossover to statin use confound the interpretation of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) trial, which found a less than expected reduction in coronary and stroke events with fenofibrate. Of concern, nonsignificant increases in coronary and sudden deaths, thrombotic events, and pancreatitis occurred in the fenofibrate group. The PROspective pioglitAzone Clinical Trial In macroVascular Events (PROACTIVE) also found a reduction in coronary and stroke events with pioglitazone compared with placebo in a population with diabetes and cardiovascular disease, but this benefit was counterbalanced by an increase in congestive heart failure as well as symptomatic edema. Further research is needed to determine the role of PPAR agonists in the prevention of cardiovascular disease.

Coronary Disease↗

Depressive symptoms and sex affect completion rates and clinical outcomes in cardiac rehabilitation.

Symptoms of depression are often seen in patients with coronary heart disease. Symptoms appear more commonly in women and are negatively associated with measures of cardiovascular health. Using multiple logistic regression analyses, the authors evaluated the independent effects of depression (as measured by the Beck Depression Inventory [BDI-II]) and sex on cardiac rehabilitation (CR) completion. In addition, in those who completed CR, the authors evaluated whether depressive symptoms and sex affected clinical outcomes. Women as well as participants with enrollment BDI-II scores > or =14 had significantly higher rates of CR noncompletion. Patients with BDI-II scores > or =14 who completed CR achieved significant improvements in lipid profile, body mass index, and exercise capacity regardless of sex. Women and individuals with BDI-II scores > or =14 are at risk for CR noncompletion and should be encouraged to complete CR, because cardiovascular benefits comparable to those seen in men and individuals with low BDI-II scores were achieved when these patients completed the CR program.

Coronary Disease↗